SAFEGUARDS:

In accordance with the requirements of 42 CFR 2.16, USMS EAP, contractor records are stored in a secure environment. Access to USMS EAP records is restricted to designated USMS EAP personnel, except as otherwise permitted by law or with the written consent of the individual. Vouchers prepared to effect payment for services rendered by the contractors in performance of the contract do not contain individual identifiers. Invoices prepared by contractors located outside the Washington, DC metropolitan area are sent by first-class mail to the designated member(s) of the local contractors contracted with the USMS. In turn, invoices or other records prepared in support of payment vouchers which contain individual identifiers are hand-carried by the local contractors to the EAP Administrator who retains the supporting documentation. Records are maintained in locked metal safes. Entry to headquarters is restricted by 24-hour guard service to employees with official and electronic identification.

Access to contractors records is restricted to a designated member(s) of the contractors, except as otherwise provided by law or with the written consent of the individual. Contractors records are stored in locked files also.

RETENTION AND DISPOSAL:

Records, paper or electronic, are retained for three years after the individual ceases contact with the USMS EAP and/or the contractor unless a longer retention period is necessary because of pending administrative or judicial proceedings. In such cases, the records are retained for six months after the case is closed. At that time the records are destroyed by shredding (General Records Schedules 26 and 36).

SYSTEM MANAGER(S) AND ADDRESS:

Employee Assistance Program Administrator, Health and Safety Team, Human Resources Division, United States Marshals Service, CS–3, Washington, DC 20530–1000.

NOTIFICATION PROCEDURE:

Same as ''Record access procedures.''

RECORD ACCESS PROCEDURES:

Address all requests for access to the USMS EAP records in writing to system manger identified above. Address all requests for records maintained by the contractor to these service providers. Address(es) of these service providers may be obtained by contacting the USMS EAP Office. Clearly mark the envelope and letter ''Privacy Act Request.'' Clearly indicate the name of the requester, nature of the record sought, and approximate date of the record. In addition, provide the required verification of identity (28 CFR 16.41(d)) and a return address for transmitting the information.

CONTESTING RECORD PROCEDURES:

Direct all requests to contest or amend information in accordance with the procedures outlined under ''Record access procedures.'' State clearly and concisely the information being contested, the reasons for contesting it, and the proposed amendment to the information sought. Clearly mark the letter and envelope ''Privacy Act Amendment Request.''

RECORD SOURCE CATEGORIES:

Records are generated by the EAP client who is the subject of the record; USMS EAP personnel; the contractors, and the specialized service providers; the USMS Human Resources Division; and the employee's supervisor. In the case of a confirmed, unjustified positive drug test, records may also be generated by the staff of the Drug-Free Workplace Program and the Medical Review Officer.

EXEMPTIONS CLAIMED FOR THE SYSTEM:

None.

[FR Doc. E7–16894 Filed 8–24–07; 8:45 am]

BILLING CODE 4410–04–P

DEPARTMENT OF JUSTICE

Antitrust Division

Notice Pursuant to the National Cooperative Research and Production Act of 1993—the Nanoparticle Flow Processing Consortium

Notice is hereby given that, on July 16, 2007, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* (''the Act''), Nanoparticle Flow Processing Consortium has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing (1) the identities of the parties to the venture and (2) the nature and objectives of the venture. The notifications were filed for the purpose of invoking the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances.

Pursuant to Section 6(b) of the Act, the identities of the parties to the venture are: 3M Company, St. Paul, MN; The Proctor & Gamble Company, Cincinnati, OH; Corning Incorporated, Corning, NY; BASF Aktiengesellschaft, Ludwigshafen, Germany, and Imperial Chemical Industries PLC, London, United Kingdom. The general area of Nanoparticle Flow Processing Consortium's planned activity is to: (1) Develop, test, and validate computer-simulation technologies of near-term application that can improve the quality and reduce the cost of nanoparticle suspension/dispersion manufacture (including suspension stability and processibility); (2) transfer the technology developed under the Research and Development Program in a manner that offers the Consortium members opportunities for commercial advantage; and (3) develop methodologies and aptitude for modeling and simulation of multiscale phenomena intrinsic to the stability and dynamics of dense, nanoparticle suspensions. This development will be synergistic and applicable to many U.S. Department of Energy campaigns for simulation (viz. C6, ASC, and other science and technology initiatives like those underpinning MESA).

J. Robert Kramer II,

Director of Operations, Antitrust Division.

[FR Doc. 07–4166 Filed 8–24–07; 8:45 am]

BILLING CODE 4410–11–M

DEPARTMENT OF JUSTICE

Antitrust Division

Notice Pursuant to the National Cooperative Research and Production Act of 1993—National Center for Manufacturing Sciences, Inc.

Notice is hereby given that, on July 24, 2007, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* (''the Act''), National Center for Manufacturing Sciences, Inc. (''NCMS'') has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Ahura Scientific, Inc., Wilmington, MA; Ben Franklin Technology Partners, Philadelphia, PA; Camber Corporation, Huntsville, AL; City of Detroit Information Technology Services Dept., Detroit, MI; Electro-Mechanical Associates, Inc., Ann Arbor, MI; H.A. Burrow Pattern Works, Inc., La Habra, CA; I.D. Systems, Inc., Hackensack, NJ; MichBio, Ann Arbor, MI; Oxonica plc, Mountain View, CA; Purdue University, West Lafayette, IN;

Radian Tool & Engineering, Troy, MI; and Savant Technology Group, Inc., Ann Arbor, MI have been added as parties to this venture. Also, Anautics, Inc., Oklahoma City, OK; Campfire Interactive, Inc., Ann Arbor, MI; Cleveland Advanced Manufacturing Program (CAMP), Cleveland, OH; Cor-Met Inc., Brighton, MI; Fraunhofer USA, Plymouth, MI; Integrated Technologies, Inc., Danville, VT; Leszynski Group Inc., Bellevue, WA; Midwest Thermal Spray, Farmington Hills, MI; and Raytheon Systems Company, McKinney, TX have withdrawn as parties to this venture.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and NCMS intends to file additional written notification disclosing all changes in membership.

On February 20, 1987, NCMS filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to Section 6(b) of the Act on March 17, 1987 (52 FR 8375).

The last notification was filed with the Department of Justice on February 15, 2007. A notice was published in the **Federal Register** pursuant to Section 6(b) of the Act on March 15, 2007 (72 FR 12198).

J. Robert Kramer II,

Director of Operations, Antitrust Division.

[FR Doc. 07–4165 Filed 8–24–07; 8:45 am]

BILLING CODE 4410–11–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Registration

By Notice dated April 17, 2007, and published in the **Federal Register** on April 30, 2007, (72 FR 21298), Amri Rensselaer, Inc. (formerly: Organichem Corporation), 33 Riverside Avenue, Rensselaer, New York 12144, made application by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Oxymorphone (9652), a basic class of controlled substance listed in schedule II.

The company plans on manufacturing the listed controlled substance in bulk for sale to its customer.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Amri Rensselaer, Inc. to manufacture the listed basic class of controlled substance is consistent with the public interest at this time. DEA has investigated Amri Rensselaer, Inc. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic class of controlled substance listed.

Dated: August 16, 2007.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. E7–16856 Filed 8–24–07; 8:45 am]

BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on June 5, 2007, Boehringer Ingelheim Chemicals Inc., 2820 N. Normandy Drive, Petersburg, Virginia 23805, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule I and II:

Drug	Schedule
Tetrahydrocannabinols (7370)	I
Amphetamine (1100)	II
Methylphenidate (1724)	II
Methadone (9250)	II
Methadone Intermediate (9254)	II
Dextropropoxyphene, bulk (non-dosage forms) (9273).	II
Fentanyl (9801)	II

The company plans to manufacture the listed controlled substances in bulk for sale to its customers for formulation into finished pharmaceuticals.

Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537, or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 2401 Jefferson Davis Highway, Alexandria, Virginia 22301; and must be filed no later than October 26, 2007.

Dated: August 16, 2007.

Joseph T. Rannazzisi,

Deputy Assistant Administraton, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. E7–16855 Filed 8–24–07; 8:45 am]

BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importer of Controlled Substances; Notice of Application

Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in schedule I or II and prior to issuing a regulation under 21 U.S.C. 952(a)(2) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing.

Therefore, in accordance with Title 21 Code of Federal Regulations (CFR), 1301.34(a), this is notice that on June 5, 2007, Boehringer Ingelheim Chemicals, Inc., 2820 N. Normandy Drive, Petersburg, Virginia 23805, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of Phenylacetone (8501), a basic class of controlled substance listed in schedule II.

The company plans to import the listed controlled substance to bulk manufacture amphetamine.

Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic class of controlled substance may file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47.

Any such comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC